All articles by Abigail Beaney

Abigail Beaney

Abigail Beaney is a pharmaceutical reporter for the Clinical Trials Arena. Abigail holds a BA (Hons) in Journalism from the University of Central Lancashire. Abigail has an expertise in trial design, cell and gene therapies and neurodegenerative diseases. Contact Abigail

Pfizer drops obesity pill development after liver injury report

Pfizer has terminated the development of its oral obesity candidate danuglipron after a patient on a clinical trial with the…
UK Government to invest $764m into new health data service

The UK Government has announced a £600m ($764m) funding pot to create a new Health Data Research Service, reducing red…
Rhythm seeks market expansion for Imcivree following Phase III victory

Rhythm Pharmaceuticals is pursuing approval for its rare obesity disorder drug Imcivree in acquired hypothalamic obesity after it showed a…
Cassava ends simufilam Alzheimer’s programme after second Phase III failure

Cassava Sciences has officially stopped the development of its investigational drug simufilam in Alzheimer’s disease after it failed to show…
Rising Sirturo resistance highlights urgent need for new TB therapies

There have been widespread reports that more effort and funding is needed to combat the TB crisis. As more cases…

Roche’s discontinued Alzheimer’s drug shows signs of preventing onset

Roche’s discontinued Alzheimer’s disease drug has shown signs that it could prevent onset of the disease. The Phase II/III Knight…
J&J drops Phase III MDD programme due to lack of efficacy

Johnson & Johnson (J&J) is dropping its Phase III major depressive disorder (MDD) programme for aticaprant due to ‘insufficient efficacy…
Tris Pharma eyes approval after pain drug triumphs in second Phase III trial

Tris Pharma has reported another Phase III win with its investigational pain therapy, cebranopadol, and it is now setting up…
USAID: sponsors, agencies and foundations may have to fill funding gap

A shutdown of funding for the US Agency for International Development (USAID) could lead to the termination of clinical trials…
OCT West Coast 2025: Recruitment and regulation remain pain points

A packed agenda at Arena International’s Outsourcing in Clinical Trials (OCT) West Coast 2025 conference, which took place at the…